DENVER, CO, September 14, 2005, GlobeImmune, Inc., a biopharmaceutical company developing immunotherapy products called Tarmogens™ for the treatment of cancer and chronic infectious diseases, today announced the initial successful closings of a Series B Preferred Stock financing, raising $34.3 million. … Continue reading
Globelmmune Raises Over $34 Million in Series B Financing
September 14, 2005